Faculty Bibliography

BACKGROUND AND OBJECTIVES/OBJECTIVE:Interactions between cancer cells and their microenvironment are central to tumor formation. Regional microenvironmental variability in the brain may offer insights into essential factors in tumorigenesis. Surprisingly, a granular assessment of regional patterns of gliomagenesis has not been undertaken in the molecular era. The aim of this study was to quantitatively establish the anatomic distribution of the major molecular subtypes of adult diffuse glioma. METHODS:We retrospectively analyzed 204 isocitrate dehydrogenase (IDH)-mutant and 200 IDH-wildtype gliomas. Reproducibility was assessed in an external cohort (190 IDH-mutant, 227 IDH-wildtype), and microarray expressions from Allen Human Brain Atlas were used to compare transcriptomic profiles between IDH-mutant hotspots and coldspots. RESULTS:A total of 50.5% (103/204) of IDH-mutant tumors arose with the superior and middle frontal gyri, indicating a 3.1-fold regional enrichment relative to the volume of these gyri (P < .001). Totally, 9.5% (19/200) of IDH-wildtype tumors arose in the superior temporal gyrus with a 2.1-fold enrichment (P = .01). IDH-mutant and wildtype tumors were enriched by 4 and 4.5-fold, respectively, in the insula (both P < .001). Overall, 23.3% (24/103) of astrocytomas occurred disproportionately higher in the insula compared with oligodendrogliomas (P < .001). Transcriptomic analysis comparing the lobar hotspot (frontal lobe) to the coldspot (occipital lobe) revealed frontal enrichment of cholesterol (normalized enrichment score = 1.78) and fatty acid (normalized enrichment score = 1.94) metabolism pathways, paralleling the observed regional enrichment of IDH-mutant gliomas. CONCLUSION/CONCLUSIONS:This study identifies molecular subtype-specific glioma hotspots and may suggest that regional metabolic differences may underlie the brain's variable vulnerability to gliomagenesis. These findings provide a framework for investigating additional microenvironmental factors that drive human glioma formation.

Oral medicine is the dental specialty dedicated to the oral health care of medically complex patients and the diagnosis and management of medically related diseases, disorders, and conditions affecting the oral and maxillofacial region. Like other dental and medical specialties, oral medicine patient care is often impacted by challenges such as limited manpower, time, or resources. Artificial intelligence (AI) tools seek to supersede these challenges by automating human tasks and ushering greater efficiency and productivity. For direct patient care in oral medicine, AI has applications in risk prediction modeling, diagnosis establishment, treatment decision-making, and prognosis and outcomes prediction modeling.

Oral medicine is the dental specialty dedicated to the oral health of medically complex patients and the diagnosis and management of medically-related diseases, disorders, and conditions affecting the oral and maxillofacial region. In addition to direct patient care, Oral Medicine specialists often engage in indirect patient care activities such as patient education and practice administration and/or academic activities such as student education and research. Artificial intelligence (AI) tools have been increasingly studied to facilitate these domains and contribute to more positive outcomes for practitioners, patients, and students alike. A review of the literature on these AI applications in Oral Medicine and related medical and dental fields provides an understanding of their current advantages and limitations.

OBJECTIVES/UNASSIGNED:This ASPO survey investigates pediatric peri-operative tracheostomy care practices through a nationwide survey. It aims to identify challenges, explore opportunities for standardization across institutions, and recommend strategies that could reduce complications and enhance patient care. METHODS/UNASSIGNED:A 19-question survey was administered online to pediatric otolaryngologists. Descriptive statistics summarized respondent demographics and responses. RESULTS/UNASSIGNED:Of 138 respondents, 90% practiced in the US, primarily in the Mid-Atlantic and Great Lakes. Over 60% performed fewer than 10 pediatric tracheostomies annually. A majority (98%) used stay sutures for accidental decannulation, and 25% did not mature the stoma. Notably, 92% adhered to standardized post-operative protocols. Bivona tracheostomy tubes were most commonly used (72%). First tube changes were typically on postoperative Days 5 and 7, with false passage creation (46%) and bleeding (41%) as primary complications. Routine surveillance bronchoscopy was conducted by 63%, mainly twice in the first year (34%). CONCLUSION/UNASSIGNED:The survey highlights wide variation in pediatric tracheostomy practices and underscores the importance of standardized protocols. Most respondents perform fewer than 10 procedures each year, yet adherence to institutional guidelines reflects a strong commitment to safety. This study identifies key areas of variability such as the timing of the first tube change, use of surveillance bronchoscopy, and reported complications-and outlines opportunities for further research and standardization aimed at improving consistency and clinical outcomes. LEVEL OF EVIDENCE/UNASSIGNED:5.

INTRODUCTION/UNASSIGNED:The Clinical Toxicology Recommendations Collaborative was established by three international clinical toxicology societies and tasked to produce recommendations on the management of poisonings. The Activated Charcoal in Clinical Toxicology Workgroup (the Workgroup) was formed to provide recommendations on the administration of activated charcoal for gastrointestinal decontamination and enhanced elimination in poisoning. METHODS/UNASSIGNED:Based on a systematic review of the literature, 43 poisons or poison categories were selected for appraisal. Voting statements were drafted using a predetermined format. Strength of consensus was measured using the Disagreement Index as defined by the RAND/University of California at Los Angeles Appropriateness Method. A two-round modified Delphi method was used to reach expert consensus. RESULTS/UNASSIGNED:The Workgroup concluded that there is no role for activated charcoal in poisoning from arsenic, caesium, copper, ethanol, methanol, ethylene glycol, iron, lead, lithium, and metformin. Activated charcoal is appropriate after ingestion of antidysrhythmics (types I and III not discussed specifically), beta-adrenergic antagonists, bupropion, calcium-channel blockers, carbamazepine, cardiac glycosides, chloroquine, cocaine, colchicine, cyanide, dapsone, diphenhydramine, disopyramide, factor Xa inhibitors, ibuprofen, isoniazid, lamotrigine, methotrexate, moclobemide, opioids, organophosphorus insecticides, paracetamol (acetaminophen), paraquat, phenobarbital, phenytoin, quinidine and quinine, salicylates, selective serotonin reuptake inhibitors, sulfonylureas, thallium, theophylline, tricyclic antidepressants, valproic acid, venlafaxine, and warfarin. An additional dose of activated charcoal to complete gastrointestinal decontamination is appropriate after ingestion of carbamazepine, paracetamol, paraquat, phenobarbital, salicylates, thallium, theophylline, valproic acid and verapamil. The maximum time post-ingestion for which activated charcoal administration is recommended differs for each poison and different formulations. According to an individualized risk assessment, activated charcoal is appropriate up to 6 h post-ingestion for many poisons. If ongoing absorption is suspected, which may occur, for example, with pharmacobezoar formation, certain modified-release preparations, or when drug burden exceeds the limits of solubility, then activated charcoal can be administered beyond 6 h post-ingestion for gastrointestinal decontamination. Multiple-dose activated charcoal for enhanced elimination is appropriate in poisoning with carbamazepine, cardiac glycosides, colchicine, dapsone, phenobarbital, phenytoin, thallium and theophylline. UNLABELLED: DISCUSSION/UNASSIGNED:The decision to use activated charcoal is complex and depends primarily on the nature of the poison(s), the time since ingestion, the severity of the symptoms present at the time of decision or expected based on the dose ingested or patient comorbidities, and the availability of antidotes or other treatments. Although the existing level of evidence is primarily of low or very low quality, clinical decisions are still necessary. CONCLUSIONS/UNASSIGNED:The Workgroup recommends the administration of a single-dose of activated charcoal beyond the traditional 1 h post-ingestion time point in selected poisons and introduces the concept of an additional dose of activated charcoal to prevent further absorption of poisons that may remain in the gastrointestinal tract for prolonged periods of time. Multiple-dose activated charcoal is also recommended to enhance elimination in selected clinical scenarios.

OBJECTIVE:To define oncologic outcomes in Veterans in the modern era using a multi-institutional cohort designed to support development and validation of prognostic and predictive biomarkers for oropharyngeal squamous cell carcinoma (OPSCC). METHODS:A retrospective analysis was conducted including adult OPSCC patients treated at one of nine Veterans Affairs Medical Centers between 2000 and 2024; inclusive of 597 HPV-associated and 197 HPV-independent tumors. All patients were treated with curative intent external beam radiotherapy (100%) with (90%) or without concurrent chemotherapy. RESULTS:A total of 894 adult patients (mean age, 64 years; 881 (99.5%) male) were included in the study; 22% of patients self-identified as Black. The estimated 2- and 5-year OS rates for the entire cohort were 71% and 54%, respectively and lagged substantially behind locoregional control (LRC) and distant metastatic control (DMC). For Veterans with HPV-associated OPSCC, LRC and DMC at 5 years were 87% and 87% respectively. The strongest drivers of OS and LRC were T-classification and chemotherapy choice on univariate and multivariate analysis. CONCLUSIONS:Although LRC and DMC rates among Veterans track well with recently completed clinical trial outcomes, OS rates lag substantially suggestive of higher rates of non-cancer-specific mortality. Together, these data suggest that predictive biomarker strategies focused on treatment effectiveness should be predicated on LRC and DMC rather than OS. This multicenter study is the first step in providing a robust dataset capable of developing and optimizing artificial intelligence (AI)-informed prognostic and predictive strategies essential to a precision oncology approach to OPSCC.

Spinal tumor surgery requires rapid tissue diagnosis to guide surgical decisions and further treatment strategies, yet current intraoperative methods are time-intensive and require specialized expertise. No AI systems exist for real-time spinal tumor classification during surgery. We developed SpineXtract, the first AI-powered system for rapid intraoperative spinal tumor diagnosis using stimulated Raman histology (SRH) - a label-free Raman spectromics imaging technique without tissue processing available during surgery. We created a transformer-based classifier optimized for spinal tissue characteristics to identify common tumor types: meningioma, schwannoma, ependymoma, and metastasis. The system was tested in an international, multicenter, simulated, single-arm study using existing SRH datasets (44 patients, 142 slide-images) from three international institutions, with final pathological diagnosis as reference standard. SpineXtract achieved a 92.9% macro-average balanced accuracy (95% CI: 85.5-98.2) within 5 minutes (tumor-specific accuracy range, 84.2-98.6%), while providing quantitative microscopic feedback for granular tissue analysis. Performance remained consistent across institutions (macro balanced accuracy 91.4-92.0%) and outperformed existing brain tumor classifiers by 15.6%. Our results demonstrate clinical applicability, enabling rapid intraoperative diagnosis with performance exceeding current methods, potentially transforming intraoperative diagnostic workflows in spinal tumor surgery.

Facial nerve palsy is a debilitating condition with substantial physical and psychosocial impacts. Facial reanimation encompasses surgical reconstructive procedures aimed at restoring the functions of the facial nerve to improve function and quality of life in patients with facial palsy. This educational review outlines the essential principles for interpreting imaging studies for facial reanimation including fundamental anatomy, technical descriptions and imaging appearances of common reconstructive procedures, and key findings that should be included when reporting studies for patients being considered for facial reanimation. The information provided in this review equips radiologists to contribute effectively to a multidisciplinary team necessary for the treatment of patients with facial nerve palsy.

OBJECTIVE:Nasolacrimal duct obstruction (NLDO) in children typically resolves without surgery. Endoscopic dacryocystorhinostomy (En-DCR) is considered in cases refractory to irrigation, probing, and/or stent placement. The incidence of revision after pediatric En-DCR ranges from 0% to 22%. The objective of this review is to determine the incidence of revision and failure after pediatric En-DCR. DATA SOURCES/METHODS:In this systematic review, Medline, Embase, and Cochrane databases were searched on 11/21/2025. REVIEW METHODS/METHODS:Studies investigating primary, pediatric En-DCR outcomes were included. Case reports and articles that published no primary data or reported results aggregated with data from adult, revision, or external DCRs were excluded. Two reviewers (M.H. and R.W.) selected studies using these criteria and assessed quality with the Newcastle-Ottawa Scale and Cochrane Risk of Bias Tool. R V4.1.1 and GraphPad Prism 10.3.1 were used in statistical analysis and creation of Forest plots. The study protocol was pre-registered with Prospero. RESULTS:Thirty-one studies were included, involving 1470 ducts in 1230 patients. The mean age of these patients was 5.3 years old, and the study population was 49.5% male. Revision was performed in 9.1% of cases, and surgical failure occurred in 11.7% of cases. The mean follow-up time was 17.4 months. CONCLUSION/CONCLUSIONS:En-DCR is an effective treatment for NLDO. The incidence of revision was found to be lower than that of surgical failure, potentially due to short follow-up times of some studies or reluctance to undergo revision. The calculated incidence of complications and revision may underestimate true values due to significant heterogeneity among studies.